AlkermesALKS +4.96%70 Beneish M-Score is -1.40 as of Jun. 25, 2026. GuruFocus rates ALKS with a GF Score™ of 70/100 and a GF Value™ of $31.33 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 911 Drug Manufacturers companies, Alkermes ranks worse than 88.8% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Warning Sign:
Beneish M-Score -1.4 higher than -1.78, which implies that the company might have manipulated its financial results.
The historical rank and industry rank for Alkermes's Beneish M-Score or its related term are showing as below:
ALKS'
s Beneish M-Score Range Over the Past 10 Years
Min: -3.4 Med: -2.8 Max: -1.4
Current: -1.4
During the past 13 years, the highest Beneish M-Score of Alkermes was -1.40. The lowest was -3.40. And the median was -2.80.
Alkermes Beneish M-Score Related Terms
Alkermes Beneish M-Score Historical Data
* Premium members only.
The historical data trend for Alkermes's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALKS vs LNTH, HIMS, LQDA: Beneish M-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alkermes Beneish M-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alkermes's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Alkermes's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Alkermes for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 1.2276
+
0.528 * 0.9744
+
0.404 * 4.4367
+
0.892 * 1.0321
+
0.115 * 0.6993
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 1.208
+
4.679 * -0.024682
-
0.327 * 2.0523
=
-1.40
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(27.898 / (27.898 + 316.326))
/
(39.173 / (39.173 + 298.835))
=
0.081046
/
0.115894
=
0.6993
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(152.72 - 1.618
-
256.2)
/
4258.076
=
-0.024682
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Alkermes has a M-score of -1.40 signals that the company is likely to be a manipulator.
Alkermes (ALKS) has a Beneish M-Score of -1.40 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Alkermes and its competitors. According to the industry distribution chart, Alkermes ranks #809 out of 911 companies in the Drug Manufacturers industry, placing it in the top 88.8%.
Is Alkermes' Beneish M-Score too high?
Alkermes' current Beneish M-Score is -1.40. Based on the distribution chart, Alkermes ranks #809 out of 911 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alkermes has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alkermes' Beneish M-Score compare to LNTH and HIMS?
According to the Drug Manufacturers industry distribution chart, Alkermes ranks #809 out of 911 companies for Beneish M-Score. This places Alkermes in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Alkermes and its competitors. Alkermes's current Beneish M-Score is -1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkermes stock overvalued right now?
Based on GuruFocus' analysis, Alkermes (ALKS) is currently considered Significantly Overvalued. The stock's GF Value™ is $31.33, compared to a current price of $50.45 — trading 61% above its estimated fair value. The current Beneish M-Score is -1.40. Alkermes' overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Alkermes (ALKS), the current Beneish M-Score is -1.40 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alkermes (ALKS) Overvalued in 2026?
Based on GuruFocus' analysis, Alkermes stock appears to be overvalued.
The current stock price of $50.45 is trading 61% above its estimated GF Value™ of $31.33.
GuruFocus considers Alkermes to be Significantly Overvalued.
Key valuation signals for ALKS:
Beneish M-Score: -1.40
GF Value™: $31.33 vs. price of $50.45 (61% above fair value)
No single metric tells the full story. See the ALKS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
70GF Score
Get the complete analysis for ALKS
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALKS has been successfully added to your 
